Results 91 to 100 of about 158,858 (186)

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 980-996, March 2026.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao, Junjie Ding, Jiajia Zhao, Ling Zhang, Aburough Abegesah, Yu‐qian Zhang, Cathy O'Brien, Gary J. Doherty, Allen C. Chen, KyoungSoo Lim, Song Ren, Peiming Ma, Diansong Zhou   +12 more
wiley   +1 more source

SPD Party Office-Holder Survey 1991

, 1995
Judgement on the SPD by party office-holders in the party. Topics: Length of membership in the SPD as well as in local committee; contact or cause for personally joining the party; manner of first contact on the part of the party after joining ...
SPD-Parteivorstand, Bonn
core   +1 more source

Table_1_The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer.docx

, 2022
Accumulating evidence suggests that regulatory B cells (Bregs) play important roles in inhibiting the immune response in tumors. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important molecules that maintain the balance of the ...
Sining Wang (8145588), Fang Xie (103933), Huan Du (3108267), Qin Wang (109812), Wenting Liu (412341), Yang Yang (45629), Shenghua Zhan (6633788), Longxiang PuYang (13136538), Qiuxia Qu (13136541), Xuejiao Li (1524745), Yuqiu Wan (2186284), Zhangyu Wang (12459888), Jing Lan (1699462)   +12 more
core   +1 more source

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy

Frontiers in Immunology, 2020
Programmed death protein 1 (PD-1) interaction with PD-L1 deliver immunosuppressive environment for tumor growth, and its blockade with directed monoclonal antibodies (anti-PD-1/anti-PD-L1) has shown remarkable clinical outcome.
Muhammad Khan, Muhammad Khan, Zhihong Zhao, Sumbal Arooj, Sumbal Arooj, Yuxiang Fu, Guixiang Liao   +6 more
doaj   +1 more source

Intratumoral bacteria engineered for tumor therapy

Interdisciplinary Medicine, Volume 4, Issue 2, March 2026.
This article comprehensively reviews engineered intratumoral bacteria used in tumor therapy. The concept development, characteristics, and engineering methods of intratumoral bacteria are summarized. The mechanisms and the translational significance by which engineered intratumoral bacteria interfere with tumor progression are discussed and highlighted.
Huajie Zhang, Zelin Chen, Zeyu Yao, Sishi Luo, Cheng Luo, Rui Yang, Hao Fu, Songyin Huang   +7 more
wiley   +1 more source

Assessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications

Biomedicines
Background/Objectives: Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have revolutionized cancer immunotherapy, however the clinical relevance of their soluble forms (sPD-1 and sPD-L1) remains less studied. Soluble PD-1 and PD-L1 have been
Nikolay E. Kushlinskii, Olga V. Kovaleva, Alexei N. Gratchev, Alexander A. Alferov, Yurii B. Kuzmin, Nikolai Y. Sokolov, Dmitry A. Tsekatunov, Irina B. Ryzhavskaya, Igor N. Kuznetsov, Dmitry N. Kushlinskii, Zaman Z. Mamedli, Ivan S. Stilidi   +11 more
doaj   +1 more source

Patient characteristics according to serum sPD-L1 levels pre- or post-chemoradiotherapy.

, 2019
Patient characteristics according to serum sPD-L1 levels pre- or post-chemoradiotherapy.
Tetsuro Tominaga (3387701), Noriko Yamamoto (276979), Senzo Taguchi (6400643), Takashi Akiyoshi (4056697), Masashi Ueno (4056694), Seiichi Mori (27010), Yosuke Fukunaga (4056700), Toshiya Nagasaki (3438119)   +7 more
core   +1 more source

Investigating the expression of soluble pd-l1 (spd-l1) of breast cancer patients using elisa in Hospital USM, Kelantan [PDF]

There are limited data on soluble PD-L1 (sPD-L1) in breast cancer, particularly those involving Asian (Malaysian) women, despite the fact that increased serum and plasma levels of sPD-L1 have been observed in numerous malignancies.
Anwar, Nur Amira Khairil
core  

Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activity

, 2009
L1-CAM (L1 cell-adhesion molecule), or more simply L1, plays an important role in the progression of human carcinoma. Overexpression promotes tumour-cell invasion and motility, growth in nude mice and tumour metastasis.
Altevogt, Peter, Gutwein, Paul, Bondong, Sandra, Wolterink, Silke, Kiefel, Helena, Gast, Daniela, Riedle, Svenja   +6 more
core   +1 more source

Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients

Frontiers in Pharmacology
Background: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs). Liquid biomarkers to predict irAE occurrence are urgently needed. We previously developed an ELISA system to specifically detect soluble PD-L1 (sPD-L1) with
Takeru Kashiwada, Ryotaro Takano, Ryotaro Takano, Fumihiko Ando, Fumihiko Ando, Shoko Kuroda, Yoshishige Miyabe, Yoshishige Miyabe, Ryuji Owada, Akihiko Miyanaga, Tomoko Asatsuma-Okumura, Masaaki Hashiguchi, Yoshikazu Kanazawa, Hiroshi Yoshida, Masahiro Seike, Akihiko Gemma, Yoshiko Iwai   +16 more
doaj   +1 more source